Dr Iain Hutcheson

2021

• Fakes, L. , Hutcheson, I. and Knowlden, J. 2021. The role of the glucocorticoid receptor in anti-hormone resistance in breast cancer. The British Student Doctor Journal 5 (1), pp.18-31. (10.18573/bsdj.184)

2014

• Gee, J. M. W. et al. 2014. Increased Ret signalling and impact of vandetanib in acquired tamoxifen resistant breast cancer. Cancer Research 74 (19) 738. (10.1158/1538-7445.AM2014-738)
• Jordan, N. J. et al. 2014. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Research 16 (1), pp.-. R12. (10.1186/bcr3604)

2011

• Hutcheson, I. R. et al. 2011. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Research 13 (2) R29. (10.1186/bcr2848)
• Gee, J. M. W. et al. 2011. Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation 5 (2), pp.67-77. (10.1515/HMBCI.2011.009)
• Knowlden, J. M. et al. 2011. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Research 13 (5) R93. (10.1186/bcr3018)

2010

• Knowlden, J. M. et al. 2010. O-36 Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. EJC Supplements 8 (6), pp.13-14. (10.1016/j.ejcsup.2010.06.037)
• Hutcheson, I. R. et al. 2010. Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins [Abstract]. Breast Cancer Research 12 (S1) P13. (10.1186/bcr2510)
• Knowlden, J. M. et al. 2010. Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. Breast Cancer Research 12 (S1), pp.S15. (10.1186/bcr2546)
• Thomas, N. B. P. et al., 2010. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Research and Treatment 119 (3), pp.575-591. (10.1007/s10549-009-0355-8)

2009

• Elsheikh, S. E. et al., 2009. 162 Altered Histone Modifications and their regulating enzymes in Fulvestrant resistant breast cancer cell line In Vitro [Abstract]. Laboratory Investigation 89 (S1), pp.38A-39A. (10.1038/labinvest.2008.132)
• Gee, J. M. W. et al. 2009. The dark side of antihormonal action in breast cancer. In: Hiscox, S. E. , Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer. , pp.63-84. (10.1007/978-1-4020-8526-0_4)
• Nicholson, R. I. et al. 2009. Experimental endocrine resistance: concepts and strategies. In: Hiscox, S. E. , Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer. , pp.1-26. (10.1007/978-1-4020-8526-0_1)
• Elsheikh, S. E. et al., 2009. Altered Histone Modifications and Their Regulating Enzymes in Fulvestrant Resistant Breast Cancer Cell Line In Vitro [Abstract]. Modern Pathology 22 (S1), pp.38A-39A. 162. (10.1038/modpathol.2008.210)
• Jasani, B. et al. 2009. Resistance to HER2-directed trastuzumab therapy in breast cancer. Advances in Breast Cancer 6 (3), pp.11-18.

2008

• Hurtado, A. et al., 2008. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen [Letter]. Nature 456 (7222), pp.663-666. (10.1038/nature07483)
• Bensmail, A. et al. 2008. Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor [Abstract]. Breast Cancer Research 10 (S2) O3. (10.1186/bcr1883)
• Hutcheson, I. R. , Gee, J. M. W. and Nicholson, R. I. 2008. MAP Kinase family members and endocrine response and survival in breast cancer. In: Walker, R. A. and Thompson, A. M. eds. Prognostic and predictive factors in breast cancer. 2nd ed.. London: Informa Healthcare. , pp.122-138.
• Knowlden, J. M. et al. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111 (1), pp.79-91. (10.1007/s10549-007-9763-9)
• Nicholson, R. I. et al. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. In: Pasqualini, J. R. ed. Breast cancer: prognosis, treatment and prevention. 2nd ed. London: Informa Healthcare. , pp.123-136.

2007

• Hutcheson, I. R. et al. 2007. Induction of erbB3/EGFR heterodimers mediates resistance to pertuzumab in a tamoxifen-resistant MCF-7 breast cancer cell line [Abstract]. Molecular Cancer Therapeutics 6 (Suppl), pp.3373S.
• Hutcheson, I. R. et al. 2007. Heregulin beta 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research 9 (4) R50. (10.1186/bcr1754)
• Nicholson, R. I. et al. 2007. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Reviews in Endocrine and Metabolic Disorders 8 (3), pp.241-253. (10.1007/s11154-007-9033-5)

2006

• Hutcheson, I. R. et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13 (S1), pp.S89-S97. (10.1677/erc.1.01279)
• Jones, H. E. et al. 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13 (S1), pp.S45-S51. (10.1677/erc.1.01275)
• Britton, D. J. et al. 2006. Bidirectional cross talk between ER alpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Research and Treatment 96 (2), pp.131-146. (10.1007/s10549-005-9070-2)
• Jones, H. E. et al. 2006. Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. Breast Cancer Online 9 (7) e27. (10.1017/S1470903106005451)

2005

• Knowlden, J. M. et al. 2005. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146 (11), pp.4609-4618. (10.1210/en.2005-0247)
• Nicholson, R. I. et al. 2005. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12 (S1), pp.S29-S36. (10.1677/erc.1.00991)
• Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93 (2-5), pp.257-262. (10.1016/j.jsbmb.2004.12.006)
• Gee, J. M. W. and Hutcheson, I. R. 2005. Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models [Viewpoint]. Breast Cancer Research 7 (5), pp.187-189. (10.1186/bcr1289)

2004

• Nicholson, R. I. et al. 2004. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocrine-Related Cancer 11 (4), pp.623-641. (10.1677/erc.1.00778)
• Hutcheson, I. R. et al. 2004. Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib ('Iressa') or trastuzumab (Herceptin((R))) generates cross-resistant phenotypes [Abstract]. Breast Cancer Research and Treatment 88 (S1), pp.S145-S146. (10.1007/s10549-004-3602-z)
• Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10 (1), pp.346s-354s. (10.1158/1078-0432.CCR-031206)
• Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. In: Ingle, J. N. and Dowsett, M. eds. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference. New York: Marcel Dekker. , pp.249-258.

2003

• Hutcheson, I. R. et al. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81 (1), pp.81-93. (10.1023/A:1025484908380)
• Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 (3), pp.1032-1044. (10.1210/en.2002-220620)
• Britton, D. J. et al., 2003. Oestrogen receptor phosphorylation in hormone sensitive and anti-hormone resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82 (S1), pp.S61. (10.1023/A:1026252325164)
• Hutcheson, I. R. et al. 2003. Heregulin-induced AKT activation promotes growth of gefitinib ('Iressa', ZD1839)-treated, tamoxifen-resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82 (S1), pp.S170. (10.1023/A:1026252325164)
• Nicholson, R. I. et al. 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80 (S1), pp.29-34. (10.1023/A:1025467500433)
• Clark, J. H. et al. 2003. Expression of adenosine receptors in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 138 , pp.U65.
• Hutcheson, I. R. , Gee, J. M. W. and Nicholson, R. I. 2003. MAP Kinase family members and endocrine response and survival in breast cancer. In: Walker, R. A. ed. Prognostic and Predictive Factors in Breast Cancer. London: Martin Dunitz. , pp.147-166.

2002

• Gee, J. M. W. et al. 2002. ZD1839 ('Iressa') improves the antitumour activity of tamoxifen ('Nolvadex') and ICI 182, 780 ('Faslodex') in antihormone responsive breast cancer [Abstract]. European Journal of Cancer 38 (S7), pp.S59. (10.1016/S0959-8049(02)80835-8)
• Nicholson, R. I. , Hutcheson, I. R. and Gee, J. M. W. 2002. Targeting of oestrogen and growth factor signalling pathways in the therapy of breast cancer: Implications for chemoprevention [Abstract]. European Journal of Cancer 38 (S3), pp.S43-S44. (10.1016/S0959-8049(02)81245-X)
• Nicholson, R. I. et al. 2002. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. In: Castagnetta, L. et al., Hormone-Related Tumors: Novel Approaches to Prevention and Treatment. Annals of the New York Academy of Sciences Vol. 963.New York: The New York Academy of Sciences. , pp.104-115. (10.1111/j.1749-6632.2002.tb04101.x)
• Clark, J. H. et al. 2002. Adenosine receptor agonists mediate the phosphorylation of mitogen activated protein kinase (MAPK) in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 135

2001

• Nicholson, R. I. et al. 2001. ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]. Clinical Cancer Research 7 (S), pp.3766S.
• Nicholson, R. I. et al. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8 (3), pp.175-182. (10.1677/erc.0.0080175)
• Chaytor, A. et al., 2001. Comparison of alpha and beta isoforms of glycyrrhetinic acid and carbenoxolone as inhibitors of EDHF-type relaxation. Presented at: Third International Symposium on Endothelium-Derived Hyperpolarizing Factor Vaux de Carnay, France 14-16 June 2000. Published in: Vanhoutte, P. M. ed. EDHF 2000. London: Taylor and Francis. , pp.115-126. (10.1201/b12802-18)

1999

• Hutcheson, I. R. et al. 1999. Nitric oxide independent relaxations to acetylcholine and A23187 involve different routes of heterocellular communication : Role of gap junctions and phospholipase A2. Circulation Research 84 (1), pp.53-63. (10.1161/01.RES.84.1.53)

1996

• Griffith, T. M. , Hutcheson, I. R. and Smith, J. A. 1996. Mechanisms of nitric oxide release from rabbit aorta and their modification by hypercholesterolemia. In: Boudoulas, H. , Toutouzas, P. K. and Wooley, C. F. eds. Functional abnormalities of the aorta. Armonk, NY: Futura Publishing. , pp.69-92.

1995

• Pugh, N. D. et al. 1995. Angiographic contrast media relax isolated rabbit aorta through an endothelium-independent mechanism that may not depend on the presence of the iodine atom. British Journal of Radiology 68 (805), pp.23-26. (10.1259/0007-1285-68-805-23)

1994

• Griffith, T. M. and Hutcheson, I. R. 1994. Modulation of endothelium-derived relaxing factor activity by flow. In: Lyall, F. and El Haj, A. J. eds. Biomechanics and cells. Cambridge: Cambridge University Press. , pp.61-80.
• Hutcheson, I. R. , Warden-Smith, J. and Griffith, T. M. 1994. Abolition of flow-dependent EDRF release before that evoked by agonists in hypercholesterolaemic rabbits. British Journal of Pharmacology 113 (1), pp.190-194.

1993

• Griffith, T. M. , Edwards, D. and Hutcheson, I. R. 1993. Flow pulsatility, arterial chaos and EDRF activity. Presented at: Recent Advances in Coronary Circulation: Two Symposia Fukushima, Japan 1993. Published in: Maruyama, Y. et al., Recent Advances in Coronary Circulation: Proceedings of Two Symposia, Fukushima, Japan, 1993. Tokyo: Springer. , pp.160-170.

1992

• Hutcheson, I. R. and Griffith, T. M. 1992. Endothelium-derived relaxing factor release is modulated both by the frequency and amplitude of pulsatile flow. Presented at: Second International Meeting on the Biology of Nitric Oxide London, UK 1991. Published in: Moncada, S. et al., The Biology of Nitric Oxide, Physiological and Clinical Aspects: Proceedings of the Second International Meeting on the Biology of Nitric Oxide, London, UK, 1991. London: Portland Press. , pp.161-164.

1991

• Boughton-Smith, N. K. et al., 1991. Inflammatory and protective mediators in experimental intestinal inflammation. Presented at: 60th Falk Symposium Freiburg-im-Breisgau, Germany 18-20 October 1990. Published in: Goebell, H. et al., Inflammatory Bowel Diseases: Progress in Basic Research and Clinical Implications: Proceedings of the 60th Falk Symposium held in Freiburg-im-Breisgau, Germany, October 18-20, 1990. Falk Symposium Vol. 60. Dordrecht: Kluwer Academic. , pp.137-152.
• Griffith, T. M. et al. 1991. Role of flow in endothelial-mediated responses. Presented at: Third International Symposium on Resistance Arteries Skörping, Denmark 21-25 May 1991. Published in: Mulvaney, M. J. et al., Resistance Arteries: Structure and Function: Proceedings of the Third International Symposium on Resistance Arteries, Rebild, Skörping, Denmark, 21-25 May 1991. International Congress Series Vol. 974. Amsterdam: Excerpta Medica. , pp.204-207.